Summary
Gilead Sciences, Inc. (GILD) announced a significant settlement with ViiV Healthcare, resolving all disputes related to the sales of its key HIV medication, Biktarvy®. This agreement, effective January 31, 2022, includes a one-time payment of $1.25 billion and an ongoing royalty of 3% on U.S. sales of Biktarvy® and bictegravir-containing products until October 2027. Gilead has already recorded a $1.25 billion pre-tax charge in the fourth quarter of 2021 related to this settlement. This settlement grants Gilead a broad worldwide license and covenant not to sue concerning bictegravir, the active ingredient in Biktarvy®. While the upfront payment and ongoing royalties represent a financial impact, this resolution eliminates ongoing litigation and potential future liabilities, providing clarity and stability for Gilead's Biktarvy® business. Investors should note the financial impact of the settlement charge and the ongoing royalty structure as factors in future profitability and cash flow.
Key Highlights
- 1Gilead Sciences reaches a global settlement with ViiV Healthcare to resolve all disputes related to Biktarvy® sales.
- 2The settlement includes a one-time payment of $1.25 billion from Gilead to ViiV.
- 3Gilead will pay an ongoing royalty of 3% on U.S. sales of Biktarvy® and bictegravir-containing products until October 5, 2027.
- 4The agreement grants Gilead a broad worldwide license and covenant not to sue for bictegravir.
- 5Gilead recorded a pre-tax charge of $1.25 billion in Cost of goods sold for the fourth quarter of 2021 related to the settlement.
- 6This settlement resolves pending litigations in the U.S. and other jurisdictions.